Compare AbbVie Inc (ABBV) vs Direxion Daily Semiconductor Bear 3X Shares (SOXS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Direxion Daily Semiconductor Bear 3X Shares — how do they compare? AbbVie Inc trades at $252.5 (market cap $449.91B), while Direxion Daily Semiconductor Bear 3X Shares trades at $4.52. The key difference: AbbVie Inc pays a 2.72% dividend while Direxion Daily Semiconductor Bear 3X Shares pays none, and AbbVie Inc is trading nearer its 52-week high, Direxion Daily Semiconductor Bear 3X Shares nearer its low. Which is the better fit depends on your goals.
| ABBV | SOXS | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $261.07 | $160.60 |
52-Week Low | $184.85 | $3.25 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.61, down 0.84% on the day, with strong technical momentum showing bullish moving average signals. The company demonstrates solid revenue growth, reaching $61.16B in 2025, though net margins have compressed to 5.79%. Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $2.65 exceeding the $2.59 forecast. Positive clinical trial results for ELAHERE in ovarian cancer and institutional buying activity support investor confidence.
AbbVie presents a favorable risk-reward profile with 68% analyst buy ratings and a $266.33 consensus price target offering 5.4% upside. Key opportunities include Skyrizi/Rinvoq growth offsetting Humira declines, while risks involve patent expirations in the 2030s and margin pressure. The stock's elevated P/E of 124.83 reflects growth expectations but warrants monitoring of execution against guidance.
SOXS, the Direxion Daily Semiconductor Bear 3X Shares ETF, is trading at $4.17, down 7.54% over the past 24 hours. The technical outlook is bearish, with moving averages signaling a downtrend and oscillators neutral. A 1-for-10 stock split is scheduled for July 15, 2026. Recent news highlights the ETF's role in betting against the semiconductor sector amid a historic AI-driven chip rally, with SOXS down 88% over six months as of May 2026.
The outlook for SOXS remains highly risky due to its inverse leveraged structure and the strong bullish trend in semiconductors. Investment opportunity exists solely for tactical, short-term traders seeking to profit from potential sector pullbacks, but risks of significant losses are elevated if the rally persists. Long-term investors should avoid due to volatility decay and structural drawbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Direxion Daily Semiconductor Bear 3X Shares
SOXS is a leveraged ETF that seeks daily investment results corresponding to 300% of the inverse (opposite) of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bearish (short) position on the semiconductor sector. Due to the effects of compounding and leverage, SOXS is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXS →
